hotspot -WSS

hotspot

author：hotspot 2025-10-01 02:14:48 - browse：95

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

hotspot

WSS

FTC loses bid to block Novant's North Carolina hospital merger

ASCO Daily Recap: CAR

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Flu vaccine reformulation won't be easy, manufacturers warn

Pumping milk in bathrooms at health conferences is common

Eli Lilly’s Zepbound improved liver scarring in mid

focus

hotspot

The next ALS data readout — overdue but important

hotspot

Cancer drug shortages should be causing more outrage

FDA sets aggressive timeline for overhauling inspection procedures

23andMe had bad news about my health. I wish a person had delivered it

Maisha Meds is a PBM, but don't call it that

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare Advantage's lean provider networks lead CMS complaints

Medical leaders decry Supreme Court decision on affirmative action

Printout prescription drug information shouldn’t go digital

The high cost of giving birth even with insurance

An outdated Medicare rule harms dementia patients with anxiety

focus

How CO2 helps viruses stay alive longer in the air

Structure Therapeutics oral GLP

The inclusion problem at the heart of rehabilitation research

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

For pregnant people, addiction treatment shouldn't mean a call to child protective services

explore

Wikipedia

hotspot

hotspot